Zacks Research Reduces Earnings Estimates for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Analysts at Zacks Research cut their FY2026 earnings estimates for shares of Avanos Medical in a research report issued on Wednesday, March 18th. Zacks Research analyst Team now expects that the company will post earnings of $1.07 per share for the year, down from their prior forecast of $1.08. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s Q1 2027 earnings at $0.27 EPS, Q3 2027 earnings at $0.25 EPS, Q4 2027 earnings at $0.26 EPS and FY2028 earnings at $0.73 EPS.

AVNS has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, December 22nd. Wall Street Zen downgraded Avanos Medical from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Avanos Medical Stock Performance

Shares of Avanos Medical stock opened at $13.48 on Friday. The stock has a market cap of $626.86 million, a price-to-earnings ratio of -8.53 and a beta of 1.07. Avanos Medical has a twelve month low of $9.30 and a twelve month high of $15.68. The company’s fifty day moving average is $13.64 and its 200 day moving average is $12.31. The company has a quick ratio of 1.26, a current ratio of 2.15 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.05. The firm had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.70 million. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The company’s revenue for the quarter was up .7% on a year-over-year basis. During the same quarter last year, the firm earned $0.43 earnings per share. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS.

Hedge Funds Weigh In On Avanos Medical

Hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC boosted its position in Avanos Medical by 46.4% during the first quarter. AQR Capital Management LLC now owns 192,864 shares of the company’s stock valued at $2,700,000 after acquiring an additional 61,095 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Avanos Medical by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after acquiring an additional 1,121 shares in the last quarter. Millennium Management LLC raised its position in shares of Avanos Medical by 508.3% in the 1st quarter. Millennium Management LLC now owns 547,740 shares of the company’s stock worth $7,849,000 after acquiring an additional 457,703 shares in the last quarter. Empowered Funds LLC lifted its stake in shares of Avanos Medical by 5.4% in the 1st quarter. Empowered Funds LLC now owns 162,182 shares of the company’s stock valued at $2,324,000 after purchasing an additional 8,348 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Avanos Medical by 17.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company’s stock valued at $2,018,000 after purchasing an additional 20,541 shares during the period. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.